ETOPOPHOS PRESERVATIVE FREE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Feb 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ETOPOPHOS PRESERVATIVE FREE is an injectable small-molecule formulation approved in 1998 for parenteral administration. The preservative-free designation indicates a specialized formulation designed for enhanced safety in sensitive patient populations. Specific indication and mechanism data are not available in current records.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), suggesting potential team restructuring and transition planning activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring on this product currently, reflecting its mature LOE-approaching status. Roles available would emphasize defending market share against generics and optimizing pricing before exclusivity loss.
Brand ManagerField Sales Representative
Worked on ETOPOPHOS PRESERVATIVE FREE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.